EpCAM expression in retinoblastoma: A novel molecular target for therapy

Investigative Ophthalmology and Visual Science

Volumn 45, Issue 12, 2004, Pages 4247-4250

  Krisbnakumar, Subramanian ^a   Moban, Adithi ^a   Mallikarjuna, Kandalam ^a   Venkatesan, Nalini ^a   Biswas, Jyotirmay ^a   Sbanmugam, Mabesb Palanivelu ^b   Ren Heidenreicb, Lifen ^c  

^a VISION RESEARCH FOUNDATION   (India)

^b MEDICAL RESEARCH FOUNDATION   (India)

^c ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; EPITHELIAL CELL ADHESION MOLECULE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY GA 733; UNCLASSIFIED DRUG;

ARTICLE; CANCER INVASION; CELL INVASION; CHILD; CLINICAL ARTICLE; CORRELATION ANALYSIS; EPITHELIUM CELL; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFANT; MALE; OPTIC NERVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINOBLASTOMA; TUMOR DIFFERENTIATION;

ADULT; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CELL DIFFERENTIATION; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MALE; NEOPLASM INVASIVENESS; RETINA; RETINAL NEOPLASMS; RETINOBLASTOMA;

EID: 9644260360     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.04-0591     Document Type: Article

References (36)

1. McLean IW, Burnier MN, Zimmerman LE, Jakobiec FA. Tumors of the retina. In: Tumors of the Eye and Ocular Adnexa. Washington, DC: Armed Forces Institute of Pathology; 1994:97-149.
2. Donaldson S, Egbert P, Newsham I, Cavenee W. Retinoblastoma. In: Pizzo P, Poplack D, eds. Principles and Practice of Pediatric Oncology. 3rd ed. Philadelphia: JP Lippincott; 1997:669-715.
3. Magrath I, Shad A, Epelman S, et al Pediatric oncology in countries with limited resources. In: Pizzo P, Poplack D, eds. Principles and Practice of Pediatric Oncology. 3rd ed. Philadelphia: JB Lippincott; 1997:1395-1420.
4. Schultz KR, Ranade S, Neglia JP, Ravindranath Y. An increased relative frequency of retinoblastoma at a rural regional referral hospital in Miraj, Maharashtra, India. Cancer. 1993;72:282-286.
5. Chantada G, Fandino A, Manzitti J, Urrutia L, Schvartzman E. Late diagnosis of retinoblastoma in a developing country. Arch Dis Child. 1999;80:171-174.
6. Suzuki S, Kaneko A. Management of intraocular retinoblastoma and ocular prognosis. Int J Clin Oncol. 2004;9:1-6.
7. Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol. 2004;22:1136-1151.
8. Went PT, Lugli A, Meier S, et al. Frequent EpCAM protein expression in human carcinomas. Hum Pathol. 2004;35:122-128.
9. r 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res. 1987;47:2883-2891.
10. Winter MJ, Nagtegaal ID, van Krieken JH, Litvinov SV. The epithelial cell adhesion molecule (EpCAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol. 2003;163:2139-2148.
11. Naundorf S, Preithner S, Mayer P, et al. In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pan carcinoma treatment. Int J Cancer. 2002;100:101-110.
12. Schwartzberg LS. Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Crit Rev Oncol Hematol. 2001;40:17-24.
13. Riethmuller G, Holz E, Schlimok G. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol. 1998;16:1788-1794.
14. Spizzo G, Obrist P, Went P, et al. Edrecolomab in the adjuvant treatment of colorectal carcinoma. Lancet. 2003;361:83.
15. Braun S, Hepp F, Kentenich CR, et al. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin Cancer Res. 1999;5:3999-4004.
16. Seligson DB, Pantuck AJ, Liu X, et al. Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res. 2004;10:2659-2669.
17. Finger PT, Harbour JW, Karcioglu ZA. Risk factors for metastasis in retinoblastoma. Surv Ophthalmol. 2002;1:1-16.
18. Utvinov SV, Velders MP, Bakker HAM, Fleuren GJ, Warnaar SO. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol. 1994;125:437-446.
19. Cirulli V, Ricordi C, Hayek A. E-cadherin, NCAM, and Ep-CAM expression in human fetal pancreata. Transplant Proc. 1995;27:3335.
20. Anderson A, Schaible K, Heasman J, Wylie C. Expression of the homophilic adhesion molecule Ep-CAM in the mammalian germ line. J Reprod Fertil. 1999;116:379-384.
21. Basak S, Speicher D, Eck S, et al. Colorectal carcinoma invasion inhibition by CO17-1A/GA733 antigen and its murine homologue. J Natl Cancer Inst. 1998;90:691-697.
22. Tandon AK, Clark GM, Chamness GC, McGuire WL. Association of the 323/A3 surface glycoprotein with tumor characteristics and behavior in human breast cancer. Cancer Res. 1990;50:3317-3321.
23. Litvinov SV, Balzar M, Winter MJ, et al. Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol. 1997;139:1337-1348.
24. Schipper JH, Frixen UH, Behrens J, et al. E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res. 1991;51:6328-6337.
25. Behrens J, Marcel MM, Van Roy FM, Birchmaier W. Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol. 1989;108:2435-2447.
26. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta. 1994;1198:11-26.
27. Shibanuma H, Hirano T, Tsuji K, et al. Influence of E-cadherin dysfunction upon local invasion and metastasis in non-small cell lung cancer. Lung Cancer. 1998;22:85-95.
28. Tucker EL, Pignatelli M. Catenins and their associated proteins in colorectal cancer. Histol Histopathol. 2000;15:251-260.
29. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL. Natural history of HLA expression during tumour development. Immunol Today. 1993;14:491-499.
30. Krishnakumar S, Sundaram A, Abhyankar D, et al. Major histocompatibility antigens and antigen-processing molecules in retinoblastoma. Cancer. 2004;100;1059-1069.
31. Helfrich W, Kroesen BJ, Roovers RC, et al. Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas. Int J Cancer. 1998;13;76:232-239.
32. Withoff S, Helfrich W, de Leij LF, Molema G. Bi-specific antibody therapy for the treatment of cancer. Curr Opin Mol Ther. 2001;3:53-62.
33. Katzenwadel A, Schleer H, Gierschner D, Wetterauer U, Elsasser-Beile U. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer. Anticancer Res. 2000;20:1551-1555.
34. Segal DM, Weiner GJ, Weiner LM, Introduction: bispecific antibodies. J Immunol Methods. 2001;248:1-6.
35. Talac R, Nelson H. Current perspectives of bispecific antibody-based immunotherapy. J Biol Regul Homeost Agents. 2000;14:175-181.
36. Ren-Heidenreich L, Davol PA, Kouttab NM, Elfenbein GJ, Lum LG. Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model. Cancer. 2004;100:1095-1103.